FDA approved Gazyva for primary membranous nephropathy after it beat tacrolimus in a 142-patient trial. Remission rates and boxed warnings.
Gazyva Becomes First FDA-Approved Drug for Primary Membranous Nephropathy, a Rare Autoimmune Disease That Attacks the Kidneys
by | Nov 16, 2026 | Uncategorized | 0 comments

Recent Comments